Monogenetic Disease Therapy Market Expanding Across Multiple Healthcare Segments

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Monogenetic Disease Therapy Market Evolve From 2026 To 2030?

The monogenetic disease therapy market size has experienced significant growth in recent times. It is anticipated to expand from $28.3 billion in 2025 to $31.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. The historical expansion of this market can be linked to progress in human genome research, the commencement of initial gene therapy trials, an uptick in rare disease diagnoses, the availability of orphan drug incentives, and improvements in viral vectors.

The monogenetic disease therapy market is anticipated to exhibit substantial growth over the next few years. It is projected to achieve a value of $45.58 billion in 2030, advancing at a compound annual growth rate (CAGR) of 10.0%. This expansion during the forecast period can be attributed to several factors, including the advancement of gene editing platforms, a greater number of rare disease pipelines, increased rates of genetic screening, enhanced funding for personalized therapies, and more widespread regulatory approvals. Key trends shaping the market in this period encompass single gene targeted therapies, the implementation of gene replacement treatment programs, RNA-based genetic treatments, gene correction strategies for rare diseases, and the development of precision genetic drugs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33229&type=smp

What Key Drivers Are Influencing The Growth Of The Monogenetic Disease Therapy Market?

The increasing acceptance of precision and personalized medicine is projected to stimulate the expansion of the monogenetic disease therapy market in the future. This medical approach customizes disease prevention, diagnosis, and treatment to an individual’s distinct genetic, molecular, or lifestyle characteristics to optimize therapeutic efficacy and reduce adverse effects. The surge in precision and personalized medicine is attributed to healthcare providers and patients seeking tailored treatments that maximize therapeutic effectiveness, minimize negative reactions, and address specific genetic, molecular, or lifestyle traits. Monogenetic disease therapy supports precision and personalized medicine by targeting a patient’s specific genetic mutation, thereby enabling highly customized and effective treatments. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Thus, the growing adoption of precision and personalized medicine is a key driver for the growth of the monogenetic disease therapy market.

Which Segment Areas Are Covered In The Monogenetic Disease Therapy Market Analysis?

The monogenetic disease therapy market covered in this report is segmented –

1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types

2) By Inheritance Pattern: Autosomal; Chromosomal

3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users

Subsegments:

1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies

2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions

3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions

4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy

5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies

What Key Developments And Trends Are Impacting The Monogenetic Disease Therapy Market?

Entities operating within the monogenetic disease therapy market are concentrating on developing advanced gene therapies, such as Duchenne muscular dystrophy (DMD)–targeted protocols, with the aim of decelerating disease progression and improving patient outcomes in the long term. These Duchenne muscular dystrophy–targeted protocols are structured clinical or therapeutic guidelines specifically designed for the diagnosis, monitoring, and management of individuals with Duchenne muscular dystrophy, focusing on slowing disease advancement, enhancing muscle function, and addressing related complications. For instance, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory patients aged four and older with DMD. The product demonstrated up to a 73% reduction in the rate of functional decline over three years when compared with an external control group, thereby emphasizing the significance of early intervention to alter the disease course and improve quality of life.

Which Leading Firms Are Contributing To The Growth Of The Monogenetic Disease Therapy Market?

Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.

Read the full monogenetic disease therapy market report here:

https://www.thebusinessresearchcompany.com/report/monogenetic-disease-therapy-market-report

Which Regions Are Poised For Strategic Growth In The Monogenetic Disease Therapy Market?

North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monogenetic disease therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Monogenetic Disease Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33229&type=smp

Browse Through More Reports Similar to the Global Monogenetic Disease Therapy Market 2026, By The Business Research Company

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795